Grade: Pharmaceutical Grade

Factory Location: Hangzhou,China

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Middle East

Sample Provided: no

Payment Terms: T/T

Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.